About
About Zhejiang Starry Pharmaceutical Co., Ltd
Zhejiang Starry Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of active pharmaceutical ingredients in China and internationally. It operates through Contrast Agent Series, Quinolone Series, CMO/CDMO, and Others segments. The company offers preparation products comprising iohexol, iopamidol, iodixanol, iodine-methyl, iodophorol, ioflufenicol, iopromide gadoxime meglumine, gadolinate dimeglumine, gadolinium, and iohexol injections; contrast agent APIs and intermediates consisting of iohexol, iopamidol, iodixanol, iodimeperidine, iopromide, iodophorol, iodophorol hydrolysate, iohexol hydrolysate, gadobacterium meglumine iodide, and triiodoisophthaloyl chloride esters; levofloxacin hydrochloride, levofloxacin, levofluorocycloester, and levofluorocarboxylic acid; and CMO and CDMO series, including loxoprofen sodium, loxoprofen acid, trimethyliodosilane, 2-iodo-5-methylbenzoic acid, methyl o-iodobenzoate, and iodobenzene. It also engages in technology promotion and application; investment; physical education; and wholesale activities. Zhejiang Starry Pharmaceutical Co.,Ltd. was incorporated in 1997 and is headquartered in Taizhou, China.
Research context
Zhejiang Starry Pharmaceutical Co., Ltd appears in PyInvesting’s Shanghai Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 6 months ago
Zhejiang Starry Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 14.4% below its 200 day moving average.
From a valuation standpoint, the stock is 6.9% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 10.3.
Zhejiang Starry Pharmaceutical Co., Ltd's total revenue sank by 7.3% to $324M since the same quarter in the previous year.
Its net income has increased by 32.6% to $59M since the same quarter in the previous year.
Finally, its free cash flow fell by 2409.2% to $-66M since the same quarter in the previous year.
Based on the above factors, Zhejiang Starry Pharmaceutical Co., Ltd gets an overall score of 1/5.